Protein Metrics Inc. and SCIEX Push New Boundaries in Biotherapeutic Development Software

Byomap™ and Byologic^® are now available to analyze data from SCIEX Mass Spectrometers 

San Carlos, Calif — Protein Metrics Inc., an innovative developer of software solutions for protein characterization and SCIEX, a global leader in life science analytical technologies, today released details of their co-marketing agreement for the use of Byomap™ and Byologic^® with SCIEX TripleTOF^® instruments. Protein Metrics supplies software to automate multiple aspects of biotherapeutic protein analysis, including the ability to integrate peak areas and track potential quality attributes for batches of therapeutic protein peptide maps, characterize and quantify post-translation modifications (PTMs) and sequence variants. SCIEX provides one of the fastest hybrid, tandem mass spectrometer, a Quadrupole-Time-of-Flight instrument for best-in-class performance to achieve simultaneous MS and MSMS data which can be processed by Protein Metrics software. The combination of the tools facilitates the tracking of biopharmaceutical attributes through product development campaigns. Being able to simultaneously track multidimensional attributes is becoming a critical factor in producing safer, more efficacious biotherapeutics, and this set of tools contributes to that process for Protein Metrics and SCIEX customers.

As the pharmaceutical and biotech industry has developed, and as more and more biotherapeutics are reaching the market, there is increased pressure to automate the analysis of large data sets. Even expert analysts cannot manually process data rapidly enough, and be expected to visually process the minutiae of peptide mapping results. Biopharmaceutical companies are expected to provide increasingly detailed analysis for the determination of quality attributes, contributing to gains in safety, efficacy, process development efficiency, and detailed product knowledge. In an era where mass spectrometry is able to dig ever deeper than before, and where fine details can be used to accurately profile all aspects of biotherapeutics, tools which facilitate this task are increasingly in demand.

With the ability to provide sequence information, to measure all detectable PTMs, and provide fragment ion information from MS/MS analyses, Byomap™ and Byologic^® are able to make the most of data from one of the world’s leading triple TOF mass spectrometers and report it to laboratory managers and scientists in concise and clear formats.

"In response to the needs and requests from our customers, we have provided flexibility and choice to those who need it" said Joe Fox, Senior Director of Pharma Business at SCIEX. "Our goal is to offer not only best-in-class system solutions but also take it a step beyond, so our customers get their expected results in the shortest possible time. The automation that is needed in the pharmaceutical industry today requires the rapid and automated analysis of large amounts of data. This agreement creates an ideal synergy between the best-in-class triple TOF MS and industry leading software allowing our customers the unique ability to improve their laboratory efficiency."

"We are excited to be working with SCIEX," said Chris Becker, President and CEO of Protein Metrics. "We look forward to having customers use our state-of-the-art protein characterization software to analyze data from the outstanding SCIEX TripleTOF^® mass spectrometers."

Learn more about Byomap™ and Byologic^®
https://www.proteinmetrics.com/products/